In summary, our data demonstrate that BIRC6 is enriched in imatinib-resistant CML cells (MYL-R), and that knockdown of BIRC6 was sufficient to increase imatinib sensitivity independent of Mcl-1. The gene discussed is BIRC6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.